Stockscreener 앱 받기
3.285
0.61%
0.005
전일 마감가:
$3.29
열려 있는:
$3.35
하루 거래량:
60,685
Relative Volume:
0.03
시가총액:
$338.79M
수익:
-
순이익/손실:
$-166.01M
주가수익비율:
-1.581
EPS:
-2.0778
순현금흐름:
$-131.32M
1주 성능:
+8.52%
1개월 성능:
+4.42%
6개월 성능:
-3.22%
1년 성능:
+3.44%
1일 변동 폭
$3.26
$3.38
1주일 범위
$3.01
$3.385
52주 변동 폭
$2.715
$6.42
Larimar Therapeutics Inc Stock (LRMR) Company Profile
명칭
Larimar Therapeutics Inc
전화
844-511-9056
주소
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Compare LRMR vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
3.2613 | 316.84M | 0 | -166.01M | -131.32M | -2.0778 |
VRTX
Vertex Pharmaceuticals Inc
|
515.11 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
662.07 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
924.51 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
316.50 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.78 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-29 | 개시 | Truist | Buy |
| 2024-10-16 | 개시 | Oppenheimer | Outperform |
| 2024-10-03 | 개시 | Wedbush | Outperform |
| 2024-10-02 | 개시 | H.C. Wainwright | Buy |
| 2024-09-04 | 개시 | Robert W. Baird | Outperform |
| 2024-04-03 | 개시 | Leerink Partners | Outperform |
| 2023-11-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-10-19 | 개시 | Guggenheim | Buy |
| 2022-02-15 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-02-10 | 개시 | JMP Securities | Mkt Outperform |
| 2021-02-01 | 개시 | William Blair | Outperform |
모두보기
Larimar Therapeutics Inc 주식(LRMR)의 최신 뉴스
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc.LRMR - PR Newswire
Larimar Therapeutics, Inc. (LRMR) Discusses Regulatory Progress and Long-Term Data for Nomlabofusp in Friedreich's AtaxiaSlideshow (NASDAQ:LRMR) 2026-07-01 - Seeking Alpha
Enterprise value to EBIT forward of Larimar Therapeutics, Inc. – LS:A2P5PP - TradingView
Larimar Therapeutics | 8-K: Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Moomoo
Wedbush Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $12 - Moomoo
LRMR Maintains by Baird -- Price Target Lowered to $5.00 - GuruFocus
A Quick Look at Today's Ratings for Larimar Therapeutics(LRMR.US), With a Forecast Between $5 to $25 - Moomoo
Larimar Therapeutics: Late-Stage FA Program Advances Amid Execution Risks (NASDAQ:LRMR) - Seeking Alpha
Larimar Therapeutics submits rolling BLA for nomlabofusp - The Pharma Letter
Buy Recommendation for Larimar Therapeutics (LRMR) Following Mar - GuruFocus
Larimar Therapeutics, Inc.(NasdaqGM:LRMR) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Larimar Therapeutics (LRMR) Faces Stock Decline After Safety Fin - GuruFocus
LRMR Stock Dips As Traders Weigh Cash Runway And Volatility - StocksToTrade
Larimar Therapeutics submits first module of rolling BLA for nomlabofusp in Friedreich’s ataxia - grafa.com
Larimar Stock Slides 15% Despite FDA Backing Rolling Submission For Rare Disease Drug - Benzinga
LRMR Stock Slides As Traders Eye Cash Runway And Volatility - StocksToTrade
Larimar Therapeutics Shares Drop Following Clinical Update and Regulatory Filing (LRMR) - Yahoo Finance
Larimar submits first module of rolling BLA for nomlabofusp - Investing.com UK
LRMR Stock Holds Support As Biotech Traders Watch Cash Runway - timothysykes.com
Why is Larimar Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Why is Larimar Therapeutics stock sliding today? - Investing.com
Larimar Therapeutics Files First Module of BLA With US FDA for Nomlabofusp - marketscreener.com
Larimar Therapeutics, Inc.(NasdaqGM:LRMR) added to Russell Microcap Growth Benchmark Index - marketscreener.com
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Larimar Therapeutics stock tumbles after clinical data release - Investing.com
Larimar Therapeutics Submits First Module of Rolling Bla and Reports Positive Open Label Data for Nomlabofusp in Friedreich?S Ataxia - marketscreener.com
Larimar Therapeutics (LRMR) Submits First Module for Accelerated Approval - GuruFocus
Larimar Advances Nomlabofusp BLA Toward Accelerated Approval - TipRanks
Larimar submits first module of rolling BLA for nomlabofusp By Investing.com - Investing.com South Africa
Larimar Therapeutics, Inc.(NasdaqGM: LRMR) added to Russell 2000 Growth Benchmark - marketscreener.com
LRMR: Nomlabofusp shows sustained FXN increases, clinical benefit, and strong regulatory progress - TradingView
Larimar Therapeutics submits first module of rolling BLA after positive nomlabofusp open‑label data - TradingView
LRMR: Nomlabofusp shows sustained FXN increases, clinical benefit, and advances toward accelerated approval - TradingView
Larimar Therapeutics Reports Positive Open Label Data and - GlobeNewswire
Larimar Therapeutics, Inc.(NasdaqGM:LRMR) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Larimar Therapeutics, Inc.(NasdaqGM: LRMR) added to Russell 3000E Growth Benchmark - marketscreener.com
Larimar Therapeutics to host investor event on Monday By Investing.com - Investing.com South Africa
Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia - The Manila Times
Larimar to discuss Friedreich’s ataxia drug data June 29 - Stock Titan
Larimar Therapeutics Up Nearly 32%, on Pace for Largest Percent Increase Since February 2024 -- Data Talk - Moomoo
Larimar Therapeutics, Inc. Actuals & Estimates (NASDAQ:LRMR) - TradingView
LRMR Forecast — Price Target — Prediction for 2027 - TradingView
Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? - Stocktwits
Larimar Therapeutics Inc (LRMR) Institutional Confidence - TradingKey
What Just Happened with Larimar Therapeutics (LRMR) and Why Does it Matter - Kavout | AI
Larimar Therapeutics Inc (LRMR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Larimar Therapeutics Inc (LRMR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Larimar Therapeutics Inc (LRMR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Larimar Therapeutics Inc (LRMR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Larimar Therapeutics Inc (LRMR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Larimar Therapeutics Inc (LRMR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Larimar Therapeutics Inc (LRMR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Larimar Therapeutics Inc 주식 (LRMR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Hamilton Thomas Edward | Director |
Feb 27 '26 |
Buy |
5.00 |
100,000 |
500,000 |
664,798 |
| THOMAS FRANK E | Director |
Feb 27 '26 |
Buy |
5.00 |
5,000 |
25,000 |
7,000 |
| SHERMAN JEFFREY W | Director |
Feb 27 '26 |
Buy |
5.00 |
5,000 |
25,000 |
5,000 |
| Flynn James E | Director |
Jul 31 '25 |
Buy |
3.20 |
9,375,000 |
30,000,000 |
9,538,945 |
1.95%
0.07%
자본화:
|
볼륨(24시간):